Looking at this filing, I need to identify the key facts from the 10-Q for Akebia Therapeutics, Inc. for the quarterly period ended September 30, 2026, filed November 5, 2026. The cover page confirms: NASDAQ:AKBA (Nasdaq Capital Market, trading symbol AKBA). The substantive content includes: company identity, filing period, shares outstanding (277,663,875 as of November 2, 2026), products mentioned (Vafseo/vadadustat, Auryxia/ferric citrate), pipeline candidates (ebribafusp/AKB-097, praliciguat, AKB-9090), loss of exclusivity for Auryxia in March 2025, large accelerated filer status, and forward-looking statements about commercialization and financial conditions. However, I notice the actual financial statements (income statement, balance sheet, cash flows) and MD&A narrative are not included in the extracted text - only the cover page and cautionary forward-looking statements section are present. I'll work with what's available, being careful not to infer figures not in the text.

Akebia Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Share count: 277,663,875 shares of common stock were outstanding as of November 2, 2026, according to the filing.
  • Filer status: The company is classified as a large accelerated filer under Rule 12b-2 of the Exchange Act, as disclosed on the cover page.
  • Marketed products: The filing identifies two approved products - Vafseo (vadadustat) and Auryxia (ferric citrate) - as commercial products in the U.S.
  • Auryxia exclusivity loss: According to the filing, Auryxia lost exclusivity in March 2025, with the company disclosing ongoing uncertainty about the timing and number of additional generic versions entering the market.
  • Pipeline candidates: The filing identifies ebribafusp (AKB-097), praliciguat, and AKB-9090 as current pipeline programs under development.
  • Post-TDAPA period: The filing references ongoing efforts to negotiate pricing, coverage, and reimbursement terms for Vafseo for the post-TDAPA period with third-party payors.

Akebia Therapeutics Discloses Quarterly Position Amid Auryxia Generic Competition

Akebia Therapeutics, Inc. (NASDAQ:AKBA), based at 180 Third Avenue, Floor 2, Waltham, MA, filed its Form 10-Q for the quarterly period ended September 30, 2026. The company reported 277,663,875 shares of common stock outstanding as of November 2, 2026. The filing is a quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, and the company confirmed it has filed all required reports during the preceding 12 months and has submitted all required Interactive Data Files electronically.

The filing identifies two commercial products: Auryxia (ferric citrate) and Vafseo (vadadustat). According to the filing, Auryxia lost exclusivity in March 2025, and the company disclosed uncertainty regarding "the timing and number of additional generic versions of Auryxia that enter the market," the pricing of such generics, and the resulting impact on Auryxia product revenue and sales volume. For Vafseo, the company flagged ongoing work to maintain contracts with dialysis organizations and other customers, including specialty distributors, and to secure adequate reimbursement for the post-TDAPA period.

The filing also identifies three pipeline programs: ebribafusp (AKB-097), praliciguat, and AKB-9090. The company disclosed forward-looking statements regarding "the initiation, timing, progress, results and market potential" of these programs, cautioning that all such statements are subject to risks and uncertainties under the U.S. Private Securities Litigation Reform Act of 1995. Additionally, the filing flags areas of ongoing operational focus including cybersecurity, manufacturing and supply, inventory levels, capital requirements, and the company's ability to operate as a going concern, among other matters.

What Was Disclosed

Akebia Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 277,663,875 shares outstanding, two marketed products facing competitive and reimbursement pressures, and three pipeline candidates, alongside a broad set of forward-looking statements subject to company cautionary language.